{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:10:59Z","timestamp":1790363459813,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T00:00:00Z","timestamp":1130371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effect of 5 mg\/day prednisolone on disease progression in patients with early rheumatoid arthritis (RA) receiving standardized disease\u2010modifying antirheumatic drug (DMARD) therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with active RA of &lt;2 years' duration were randomly assigned in a double\u2010blinded manner to receive prednisolone or placebo while starting concomitant DMARD therapy (gold sodium thiomalate or methotrexate). Hand and foot radiographs were taken at baseline and at 6, 12, and 24 months and were evaluated according to the Ratingen score and the total modified Sharp\/van der Heijde score (SHS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 192 included patients, 166 were available for the intent\u2010to\u2010treat analysis (ITT). Seventy\u2010six patients completed the study per protocol (PP). Radiographic progression (increase in the Ratingen score) was significantly less with prednisolone than with placebo. The difference in the progression rate between the groups was greatest in the first 6 months. At 24 months in the ITT population, the least squares (LS) mean difference was 3.14 (95% confidence interval [95% CI] 0.94, 5.34),<jats:italic>P<\/jats:italic>= 0.006. The results were confirmed by the total SHS in the ITT population (LS mean difference 7.20 [95% CI 0.93, 13.47],<jats:italic>P<\/jats:italic>= 0.022) and with the PP population. Clinical and functional outcomes tended to be better and the rate of remissions was higher in the prednisolone group. Side effects were observed more frequently in the prednisolone group than in the control group: weight gain (4 versus 0 patients), hypertension (6 versus 2 patients), glaucoma (3 versus 0 patients), Cushing's syndrome (5 versus 0 patients), gastric distress (9 versus 4 patients), and gastric ulcers (only with concomitant nonsteroidal antiinflammatory drug therapy; 3 versus 0 patients). No new lumbar fractures were found in either group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The very low daily dose of 5 mg prednisolone given over 2 years in combination with background DMARD therapy substantially decreased radiographic progression in early RA at low risk.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.21421","type":"journal-article","created":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T23:47:06Z","timestamp":1130456826000},"page":"3371-3380","source":"Crossref","is-referenced-by-count":244,"title":["Very low\u2010dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"52","author":[{"given":"Siegfried","family":"Wassenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Low\u2010Dose Prednisolone Therapy Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270805"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7134.811"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391107"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4873.1223"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effect of a hormone of the adrenal cortex (17\u2010hydroxy\u201011\u2010dehydro\u2010corticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench PS","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.18.3.173"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.14.4.353"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.16.3.277"},{"key":"e_1_2_6_10_2","first-page":"1885","article-title":"Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone","volume":"19","author":"Pincus T","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_2","first-page":"829","article-title":"What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?","volume":"22","author":"Criswell LA","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.3.207"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330302"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-1-200201010-00006"},{"key":"e_1_2_6_15_2","first-page":"1632","article-title":"Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis","volume":"27","author":"Paulus HE","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.11.713"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014050"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(91)90047-4"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.10.1060"},{"key":"e_1_2_6_21_2","first-page":"2306","article-title":"Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence","volume":"29","author":"Bruynesteyn K","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_22_2","first-page":"2094","article-title":"A new method of scoring radiographic change in rheumatoid arthritis","volume":"25","author":"Rau R","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92442-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300603"},{"key":"e_1_2_6_25_2","first-page":"71","article-title":"Die entwicklung der Funktionskapazit\u00e4t und der Schmerzintensit\u00e4t von 81 cP\u2010Patienten unter einer behandlung mit Azulfidine RA oder Aurothioglucose: vorl\u00e4ufige statistische Auswertung der multizentrischen deutschen Studie zur Behandlung der chronischen Polyarthritis mit Azulfidine RA","volume":"46","author":"Raspe HH","year":"1987","journal-title":"Z Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003930050030"},{"key":"e_1_2_6_27_2","volume-title":"Allgemeine Depressionsskala (ADS)","author":"Hautzinger M","year":"1992"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780241012"},{"key":"e_1_2_6_29_2","volume-title":"An introduction to medical statistics","author":"Bland JM","year":"1987"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20204"},{"key":"e_1_2_6_31_2","first-page":"1814","article-title":"Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis","volume":"21","author":"Van Gestel AM","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.11.1154"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<468::AID-ART367>3.0.CO;2-A"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<462::AID-ART366>3.0.CO;2-V"},{"key":"e_1_2_6_35_2","first-page":"713","article-title":"Low dose prednisone therapy in rheumatoid arthritis: a double blind study","volume":"10","author":"Harris ED","year":"1983","journal-title":"J Rheumatol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.8.874"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01300-7"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10083"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.10.1082"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.3.297"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.4.347"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.930"},{"key":"e_1_2_6_44_2","first-page":"1207","article-title":"Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls","volume":"21","author":"McDougall R","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90131-7"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1383"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-1-200201010-00013"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.21421","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.21421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:56:20Z","timestamp":1736060180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.21421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,27]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1002\/art.21421"],"URL":"https:\/\/doi.org\/10.1002\/art.21421","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,27]]}}}